SCHEMBL861523

SCHEMBL861523

O=C1NC(=O)/C(=C\c2cnn3ccc(-c4ccccc4F)nc23)S1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.52
PIK3CG P48736 1/20 0.47
MGAM O43451 2/20 0.46
GAA P10253 2/20 0.46
SI P14410 2/20 0.46
MGAM2 Q2M2H8 2/20 0.46
MTOR P42345 2/20 0.43
PIM1 P11309 5/20 0.42
PIM2 Q9P1W9 5/20 0.42
PIM3 Q86V86 2/20 0.42
TTR P02766 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
AKR1B1 P15121 1/20 0.42
NAT1 P18440 1/20 0.41
TDP2 O95551 1/20 0.41
CASP7 P55210 1/20 0.41
CASP9 P55211 1/20 0.41
CASP6 P55212 1/20 0.41
CASP8 Q14790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12979174 1.00 IGF1R (0.52) IGF1RPIK3CGMGAMGAASI
SCHEMBL861524 1.00 IGF1R (0.52) IGF1RPIK3CGMGAMGAASI
SCHEMBL3482962 0.90 MTOR (0.51) MTORPIM1NAT1GSK3BHPGD
SCHEMBL3483024 0.90 MTOR (0.51) MTORPIM1NAT1GSK3BHPGD
SCHEMBL3482965 0.90 MTOR (0.51) MTORPIM1NAT1GSK3BHPGD
SCHEMBL3483235 0.81 CSNK2B (0.43) GAAKMT2AMEN1GSK3BHPGD
SCHEMBL3482801 0.81 CSNK2B (0.43) GAAKMT2AMEN1GSK3BHPGD
SCHEMBL3482803 0.81 CSNK2B (0.43) GAAKMT2AMEN1GSK3BHPGD
SCHEMBL860236 0.78 PARP1 (0.43) KMT2AMEN1GSK3B
SCHEMBL860025 0.77 PIK3CG (0.52) PIK3CGMGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 IGF1R 814/4885PIK3CG 415/4885MGAM 3831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.